Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caravaggio study of apixaban versus dalteparin for cancer-associated venous thromboembolism
NL-OMON50094Phase 3Active, not recruiting
- Sponsor
- Fondazione FADOI
- Start
- Aug 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Apixaban with Dalteparin (2 arms). Primary endpoints: Recurrent venous thromboembolism during study treatment and Major bleeding. Started Aug 2017; status: active, not recruiting.
02
Drugs
apixabandalteparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON50094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50094.